Compare Danaher Corporation (DHR) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Synopsys, Inc. — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while Synopsys, Inc. trades at $430.16 (market cap $81.55B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays a 0.8% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| DHR | SNPS | |
|---|---|---|
Market Cap | $140.88B | $81.55B |
Sector | Health | Technology |
52-Week High | $242.05 | $645.59 |
52-Week Low | $161.91 | $380.47 |
Enterprise Value | $153.66B | $89.91B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Synopsys (SNPS) trades at $433.82, down 2.6% today, with a bearish technical signal from moving averages but oversold short-term RSI at 29.08. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.35 surpassing the $3.15 estimate. Revenue grew to $7.05B in 2025, though net income margin compressed to 8.91%. Valuation multiples remain elevated with a P/E of 99.27 and P/S of 9.16. Recent news highlights Synopsys' strategic pivot toward AI-driven design tools and multiphysics solutions.
Outlook: Analyst consensus is bullish with an average price target of $558.33, implying 29% upside, supported by 24 buy ratings. Risks include integration challenges from the Ansys acquisition, competitive pressures in EDA software, and volatility in semiconductor capex. The stock's high valuation requires sustained execution on AI-related growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
